title: Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
abstract: We report on a 70-year-old man affected by radioiodine-refractory differentiated thyroid cancer (DTC) in whom metastases were treated by peptide receptor radionuclide therapy (PRRT). Seven years before, patient had undergone total thyroidectomy. Pathological examination was conclusive for DTC. The patient underwent some radioiodine treatments (RaIT). The last post-therapy whole body scan (pT-WBS) performed five days after RaIT did not show abnormal radioiodine uptake but serum thyroglobulin (Tg) value was high in absence of thyroglobulin-antibodies (Tg-Ab). In-111 DTPA-pentetreotide scintigraphy showed several lung lesions with high somatostatin receptor density. Patient underwent PRRT using Lu-177 DOTATOC. pT-WBS scan confirmed the metastases already demonstrated by In-111 DTPA pentetreotide but radioiodine negative.
authors.affiliation: Nuclear Medicine Unit, Department of Biomedical Sciences and of Morphological and Functional Images, Padiglione E, piano terra Policlinico Universitario "G. Martino" , University of Messina, v. Consolare Valeria, 98125, Messina, Italy. acampenni@unime.it.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Campennì
authors.affiliation: Nuclear Medicine Unit, Department of Biomedical Sciences and of Morphological and Functional Images, Padiglione E, piano terra Policlinico Universitario "G. Martino" , University of Messina, v. Consolare Valeria, 98125, Messina, Italy.
authors.forename: Salvatore A
authors.initials: SA
authors.lastname: Pignata
authors.affiliation: Nuclear Medicine Unit, Department of Biomedical Sciences and of Morphological and Functional Images, Padiglione E, piano terra Policlinico Universitario "G. Martino" , University of Messina, v. Consolare Valeria, 98125, Messina, Italy.
authors.forename: Sergio
authors.initials: S
authors.lastname: Baldari
mesh_terms: D000368:Aged; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D002291:Carcinoma, Papillary; D002454:Cell Differentiation; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D009362:Neoplasm Metastasis; D015282:Octreotide / Q000031:analogs & derivatives*; D011877:Radionuclide Imaging; D018000:Receptors, Peptide; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*
chemical_list: C504257:177Lu-octreotide, DOTA(0)-Tyr(3)-; D007457:Iodine Radioisotopes; D018000:Receptors, Peptide; D015282:Octreotide
keywords: Lutetium-177; Non-radioiodine-avid differentiated thyroid cancer; Peptide radionuclide receptor therapy; Radioiodine-131